

Total Asymmetric Synthesis of *Seco*-Acids of 9,12-Anhydroerythronolide Aglycons

Simon W. Ainge and Pierre Vogel*

Section de Chimie de l'Université, BCH, CH-1015, Lausanne-Dorigny, Switzerland.


Received 12 February 1998; accepted 30 March 1998

Abstract:

The Diels-Alder adduct of 2,4-dimethylfuran to 1-cyanovinyl (1'*S*)-camphanate was converted into (2*R*,3*R*,4*S*,5*S*,6*R*,7*R*)-3,6-epoxy-4,5-isopropylidenedioxy-2,4,6-trimethyl-7-[(*tert*-butyl)-dimethylsilyloxy]non-1-yl phenyl sulfoxides (**6**), the condensation of which with (3*R*,4*S*,5*R*,6*S*)-7-benzyloxy-3,5-isopropylidenedioxy-4,6-dimethylheptan-2-one (**7**) led to the partially-protected *seco*-acid of the 9,12-anhydroerythronolide aglycon (**5**).
© 1998 Elsevier Science Ltd. All rights reserved.

Keywords: antibiotics; bicyclic heterocyclic compounds; furans; polyketides.


The urgent need for new antibiotics [1] has stimulated the search for new microorganism metabolites and of chemically-modified known antibiotics. Sporeamicin A (**1**), produced by *Saccharopolyspora* sp. L53-18A was isolated and characterized in 1992 by Morishita *et al.* [2]. It is strongly active against Gram-positive bacteria [3]. Structurally, **1** is an oxidized form of erythromycin with a 9,12-anhydro moiety. Sporeamicin B (**2**) [4] and C (**3**) [5] have also been isolated. In 1996, 6-deoxysporeamicin A (**4**) [6] was derived from 6-deoxyerythromycin A. The antibacterial spectrum of **4** is similar to that of erythromycin but is has greater potency against susceptible streptococci [6]. Other anhydro-derivatives of erythromycin A such as the neotilides (8,9-anhydro-6,9-hemiacetals) have been described and were shown to stimulate gastrointestinal motility [7].




There have been numerous investigations into the total synthesis of erythromycins [8]. None of them, however, has generated analogues containing a tetrahydrofuran ring as in **1-4**. We have shown that the readily available Diels-Alder adducts of 2,4-dimethylfuran to 1-cyanovinyl camphanates ((+)-**8**, (+)-**9**, “naked sugars of the second generation”) [9] can be converted into enantiomerically-pure polypropionate fragments of high complexity [10].

* Fax: 0041 21 692 3975 E-mail: pierre.vogel@ico.unil.ch

In this report, we demonstrate that (-)-**8** can be converted into the tetrahydrofuran derivative **6**, the condensation of which the known polypropionate fragment **7** leads to *seco*-acids of 9,12-anhydroerythronolides, potential precursors of the sporeamicins **1-4**.



Double hydroxylation of (-)-**8**, followed by protection of the diol as its acetonide and saponification of the camphanate (recovery of the chiral auxiliary, (1*S*)-camphanic acid) [10b] provided ketone (-)-**10** (78 %, 3 steps). Treatment of (-)-**10** with 1 equivalent of (*i*-Pr)₂NLi (-78 °C, 75 min, THF) and then with Me₃SiCl (-78 °C to 20 °C, 3.5 h) [11] gave enoxysilane **11** (98 %). Cyclopropanation of **11** with Et₂Zn/ICH₂Cl (ClCH₂CH₂Cl, 0 °C, 2.5 h) [12] furnished **12** which was oxidized with FeCl₃/pyridine [13] (0-40 °C, 3 h) to give the enone **13** (81 %, 2 steps). Michael addition of methylcuprate (CuBr.DMS/MeLi, Et₂O, -78 °C) followed by quenching of the enolate with Me₃SiCl (-78 °C to 20 °C, 15 h) [14] provided **14** (98 %). Oxidation of **14** (O₂/DMSO/0.09 equiv. Pd(OAc)₂, 50 °C, 2 days) [15] led to enone **15**, the hydrogenation of which, with Ph₂SiH₂/ZnCl₂/0.1 equiv. of Pd(OAc)₂(PPh₃)₂ and PPh₃ (CHCl₃, 70 °C, 4 h) [16] gave the ketone **16** with a 4-*endo* methyl substituent, as confirmed by the ¹H-NMR spectrum (³J_{H4,H5})¹). Conversion of **16** into its enol triflate [(*i*-Pr)₂NLi, THF, -78 °C, then 2-[*N,N'*-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine] [17] followed by Stille coupling with tributylvinylstannane (LiCl, 0.02 equiv. of Pd(PPh₃)₄, THF, 65 °C, 24 h) [18] provided the diene **18** (96 %). Selective reduction of the vinyl moiety into an ethyl group was achieved on treating **18** with a large excess of H₂NNH₂·H₂O and H₂O₂ (35 %) in the presence of Cu(OAc)₂ as catalyst (MeOH, -15 °C to -5 °C, 2.5 h) [19]. This gave **19** (74 %), the ozonolysis of which (O₃/CH₂Cl₂/MeOH, -78 °C; then Me₂S) and reduction with NaBH₄ (-78 °C to 20 °C, 2.5 h) furnished a 3:1 mixture of diols, the major diastereoisomer having the configuration shown in **20**, as established by X-ray crystallography²⁾.




Selective displacement of the primary alcohol moiety of **20** by phenylsulfide was possible on treatment with PhSSPh and (*n*-oct)₃P (MeCN), 20 °C, 24 h). This led to **21** (95 %, 3:1 mixture of diastereomeric alcohols, separated by flash

¹⁾ Data for (-)-**16**: Colourless oil. [α]_D²⁵ = -35, (c = 1.9, CHCl₃). IR (Film): 2984, 2936, 1725, 1379, 1217, 1084, 821. ¹H NMR (400 MHz, CDCl₃): 4.09 (*dd*, ³J = 3.6, ⁴J = 2.2, H-C(5)); 4.08 (*s*, H-C(7)); 2.61 (*ddd*, ⁴J = 2.2, ³J = 6.3, ²J = 19.2, H-C(3)); 2.56 (*ddd*, ³J = 3.6, 6.3, 14.6, H-C(4)); 2.06 (*dd*, ²J = 19.2, ³J = 14.6, H-C(3)); 1.66, 1.53, 1.48, 1.33 (4 x *s*, 4 x Me); 1.13 (*d*, ³J = 7.2, Me-C(4)). ¹³C NMR (100 MHz, CDCl₃): 206.1, 113.6, 92.4, 89.9, 89.7, 86.6, 42.3, 35.6, 29.4, 27.9, 23.0, 13.8. CI-MS (NH₃): 240 (3, *M*⁺), 225 (77, [*M-Me*]⁺), 207 (12), 189 (19), 164 (8), 135 (19), 111 (70), 97 (82), 85 (100). Anal. calc. for C₁₃H₂₀O₄: C 64.98, H 8.39. Found: C 64.94, H 8.46.

²⁾ Schenk K. Institut de Cristallographie, Université de Lausanne. Details will be given in a forthcoming full-paper.

chromatography at this stage) the major isomer being protected as a silyl ether with (*t*-Bu)₂Me₂SiOTf/2,6-lutidine (CH₂Cl₂, 0 °C, 2 h), giving **22** (89 %) ³. Oxidation of **22** with NaIO₄ in 17:1 MeOH/H₂O (20 °C, 48 h) provided **6** as a 1.5:1 mixture of two diastereoisomeric sulfoxides.

The known methylketone **7** [20] was derived from Paterson's chiron **23** [21]. Tin-aldol reaction with an excess of methacrolein (Sn(OTf)₂, Et₃N, CH₂Cl₂, -78 °C, 1 h) gave **24** (81 %, *syn/anti* selectivity: 9:1). Treatment of **24** with Bu₂BOMe, then with LiBH₄ (THF) [21] furnished a diol which was protected (Me₂C(OMe)₂, PPTS, CH₂Cl₂, 18 h) as its acetonide (**25**) (89 %, 2 steps). Ozonolysis of **25** (O₃, CH₂Cl₂, MeOH, NaHCO₃, -78 °C, then Me₂S, 0 °C to 20 °C, 10 h) provided (+)-**7** (98 %) ⁴.



The coupling of synthons **6** and (+)-**7** was realised by lithiation of **6** with LiNEt₂ (THF, -60 °C 15 min) and then addition of a THF solution of (+)-**7** (-60 °C to -25 °C, 35 min). **6** was separated from the crude mixture of adducts by flash chromatography and **26** was then desulfurized by W2-Raney nickel (Et₂O/EtOH, 20 °C, 45 min) and debenzylated (W2-Raney nickel, 1 atm H₂, EtOH, 15 h) to give a separable 5:1 mixture of diols **27a** ⁵ and **27b** (65 %).

Swern oxidation of **27a** gave aldehyde **28** which was oxidized with NaClO₂/NaH₂PO₄ (H₂O/*t*-BuOH, 2-methylbut-2-ene, 20 °C, 30 min) to the carboxylic acid **29**. Desilylation of **29** with 40 % aqueous HF (MeCN, 20 °C, 2 h) provided **5** (68 %) ⁶. The configuration of the tertiary alcohol at C⁶ in **5** was deduced from nOe measurements on **30**, a derivative of **27a** [formation of **30** by cleavage of the dioxane and the TBS ether (2 M aq. HCl, THF, 50 °C, 4 h) and then protection


³) Data for (-)-**22**: [α]_D²⁵ = -20 (c=1.88, CHCl₃). IR (Film): 2929, 1586, 1462, 1379, 1256, 826, 765, 738, 669. ¹H NMR (400 MHz, CDCl₃): 7.37 (*dd*, ⁴*J*=1.5, ³*J*=8.5, H-ortho); 7.27 (*t*, ³*J*=7.7, H-meta); 7.15 (*dt*, ⁴*J*=1.2, ³*J*=7.3, H-para); 4.23 (*s*, H-C(3)); 3.50 (*d*, ³*J*=10.3, H-(C5)); 3.46 (*d*, ³*J*=10.2, H-(C5)); 3.41 (*dd*, ³*J*=2.7, ²*J*=13.3, one of SCH₂); 3.38 (*dd*, ³*J*=3.6, 6.9 CHOSi); 2.64 (*dd*, ²*J*=13.3, ³*J*=9.1, one of SCH₂); 1.85-1.75 (fused multiplets, one of MeCH₂ and MeCH); 1.54 (*s*, Me); 1.47 (*sept*, ³*J*=7.2, one of MeCH₂); 1.35, 1.35, 1.17 (3 x *s*, 3 x Me); 1.07 (*d*, ³*J*=6.5, MeCH); 1.01 (*t*, ³*J*=7.5, MeCH₂); 0.89 (*s*, *t*-Bu); 0.12 and 0.10 (2 x *s*, 2 x MeSi). ¹³C NMR (100 MHz, CDCl₃): 137.6, 128.7, 128.3, 125.2, 113.7, 90.0, 87.9, 84.6, 84.1, 78.4, 38.2, 33.0, 28.1, 26.0, 19.5, 18.3, 15.0, 14.6, 11.2, -3.8, -4.1. CI-MS (NH₃): 403 (100, *M*⁺-PhCH₂); 345 (17); 271 (15); 229 (22); 157 (12); 91 (8). Anal. calc. for C₂₇H₄₆O₄SSi: C 65.54, H 9.37, S 6.48. Found: C 65.60, H 9.29, S 6.47.

⁴) Data for (+)-**7**: Colourless needles, m.p. 40-41 °C. [α]_D²⁵ = 30 (c=1, CHCl₃). IR (film) 3064, 3032, 2991, 2936, 2882, 1716, 1455, 1384, 1355, 1202, 1159, 1109, 1016, 985, 917, 868, 736, 699. ¹H NMR (400 MHz, CDCl₃): 7.37-7.27 (*m*, 5H, Ar); 4.49 (*br s*, PhCH₂); 4.26 (*d*, ³*J*=2.6, H-C(3)); 3.72 (*dd*, ³*J*=2.0, 9.6, H-C(5)); 3.34 (ABX system with δ_A=3.36, δ_B=3.32; ²*J*_{AB}=9.3, ³*J*_{AX}=5.3, ³*J*_{BX}=5.0, CH₂OBn); 2.16 (*s*, MeC=O); 2.04-2.01 (*m*, H-C(4)); 1.87-1.83 (*m*, H-C(6)); 1.49 (*s*, Me-(⁴Pr)); 1.41 (*s*, Me-(⁴Pr)); 1.06 (*d*, ³*J*=6.6, Me-C(4)); 0.81 (*d*, ³*J*=6.7, Me-C(6)). ¹³C-NMR (100 MHz, CDCl₃): 209.7, 138.8, 128.2, 127.5, 99.3, 79.3, 75.1, 73.1, 71.1, 34.8, 32.2, 29.7, 27.0, 19.1, 14.5, 6.3. MS (CI-NH₃): 321 (4, *M*+I⁺), 277 (10), 263 (4), 245 (13), 219 (3), 173 (3), 155 (9), 127 (7), 91 (100).

⁵) Data for (+)-**27a**: Colourless oil, [α]_D²⁵ = 3.7 (c=1, CHCl₃). ¹H NMR (400 MHz, CDCl₃): 4.19 (*s*, H-(C11)); 4.07 (*br s*, OH); 3.65 (*dd*, ³*J*=4.2, ²*J*=10.7, one of CH₂OH); 3.59 (*dd*, ³*J*=2.1, 9.3, H-(C3)); 3.55 (*dd*, ²*J*=5.4, ³*J*=10.7, one of CH₂OH); 3.52 (*d*, ³*J*=10.7, H-(C5)); 3.37 (*d*, ³*J*=10.0, H-(C9)); 3.35 (*dd*, ³*J*=2.9, 7.7, H-(COSi)); 1.86 (*dqd*, ³*J*=2.8, 7.2, 10.0, H-(C8)); 1.84-1.76 (*m*, H-(C2), H-(C4), both of H-(C7)); 1.70 (*dqd*, ³*J*=2.9, 7.7, ²*J*=15.1, one of CH₂CHOSi); 1.65-1.54 (*m*, one of CH₂CHOSi); 1.52 (*s*, Me); 1.44, 1.40, 1.39, 1.34, 1.22, 1.14 (6 x *s*, 6 x Me); 1.04 (*d*, ³*J*=6.8, Me-(C2)); 1.01 (*d*, ³*J*=6.8, Me-(C4)); 0.96 (*d*, ³*J*=7.2, Me-C(8)); 0.78 (*t*, ³*J*=7.7, MeCH₂); 0.91 (*br s*, *t*-Bu); 0.11, 0.10 (2 x *s*, 2 x MeSi). ¹³C-NMR (100 MHz, CDCl₃): 113.4, 99.1, 90.1, 87.6, 86.7, 84.7, 80.4, 78.4, 74.3, 72.7, 64.1, 45.7, 36.4, 31.2, 28.1, 27.6, 26.0, 25.0, 23.4, 19.3, 18.8, 14.1, 11.2, 7.1, -3.6, -4.2. MS (CI-NH₃): 617 (57, *M*+I⁺), 559 (100, *M*⁺-*t*-Bu), 523 (43), 483 (11), 429 (95), 367 (12), 297 (9), 255 (21), 225 (10), 173 (20) 73 (24).

⁶) Data for (+)-**5**: [α]_D²⁵ = 1.7 (c=0.5, CHCl₃). M.S. (CI-NH₃): 534 (2, *M*+NH₄⁺), 516 (1, *M*⁺), 472 (1, *M*+CO₂), 441 (7), 294 (12), 276 (62), 259 (100), 248 (9), 243 (45), 227 (12), 215 (28), 204 (20), 157 (12), 99 (22).

of four of the five OH groups of the resulting pentol ($\text{Me}_2\text{C}(\text{OMe})_2$, PPTS, CH_2Cl_2 20 °C, 2 days)] to give the *tris*-acetonide **30**. The configuration is in accord with results obtained by Stork [22] and Kochetkov [23].



The present study demonstrates that “*naked sugars of the second generation*” can be converted into polypropionate fragments containing tetrahydrofuran rings, allowing the preparation of sporeamicin aglycon analogues. Work is underway in our laboratory to convert *seco*-acids such as **5** into the corresponding macrolides.

Acknowledgements: We are grateful to the *Royal Society* (UK) for a grant to S.W.A. and to the *Swiss National Science Foundation* (CHiral 2 programme) for financial support.

References.

- [1] Chadwick DJ, Goode J, editors. *Antibiotic Resistance: Origins, Evolution, Selection and Spread*. Ciba Foundation Symposium 207. Chichester: John Wiley 1997.
- [2] Morishita A, Yaginuma S. *J. Antibiotics* 1992;45:607-612.
- [3] Morishita A, Mutoh N, Ishizawa K, Suzuki T, Yokoiyama S, Yaginuma S. *J. Antibiotics* 1992;45:613-617.
- [4] Morishita A, Murofushi S, Mutoh N, Ishizawa K, Yaginuma S. *J. Antibiotics* 1992;45:809-812.
- [5] Morishita A, Murofushi S, Mutoh N, Ishizawa K, Yaginuma S. *J. Antibiotics* 1992;45:1011-1015.
- [6] Fagih R, Freiburg L, Leonard J, Plattner JJ, Lartey PA. *J. Antibiotics* 1996;49:493-495.
- [7] See *e.g.*: Lartey PA, Nellans HN, Faghiih R, Petersen A, Edwards CM, Freiburg L, Quigley S, Marsh K, Klein LL, Plattner JJ. *J. Med. Chem.* 1995;38:1793-1798.
- [8] See *e.g.*: Martin SF, Hida T, Kym PR, Loft M, Hodgson A. *J. Am. Chem. Soc.* 1997;119:3193-3194 and references cited therein. See also: Hanessian S, Wang W, Gai Y, Olivier EJ. *J. Am. Chem. Soc.* 1997;119:10034-10041. Evans DA, Kim AS. *Tetrahedron Lett.* 1997;38:53-56.
- [9] Vogel P, Sevin A-F, Kernen P, Bialecki M. *Pure Appl. Chem.* 1996;68:719-722.
- [10] a) Sevin A-F, Vogel P. *J. Org. Chem.* 1994;59:5920-5926; b) Kernen P, Vogel P, *Helv. Chim. Acta* 1995;78:301-324.
- [11] Fleming I, Paterson I. *Synthesis* 1979:736-738.
- [12] Denmark SE, Edwards, JP. *J. Org. Chem.* 1991;56:6974-6981.
- [13] Ito Y, Fujii S, Saegusa T. *J. Org. Chem.* 1976;41:2073-2074.
- [14] Clark RD, Heathcock CH. *J. Org. Chem.* 1976;41:1396-1403.
- [15] Larock RC, Hightower TR, Kraus GA, Hahn P, Zheng D. *Tetrahedron Lett.* 1995;36:2423-2426.
- [16] Keinan E, Greenspoon N. *J. Am. Chem. Soc.* 1986;108:7314-7325.
- [17] Commins DL, Dehghani A. *Tetrahedron Lett.* 1992;33:6299-6302.
- [18] Echavarren AM, Stille JK. *J. Am. Chem. Soc.* 1987;109:5478-5486.
- [19] Corey EJ, Hortmann AG. *J. Am. Chem. Soc.* 1965;87:5736-5742.
- [20] Mulzer J, Kirstein HM, Buschmann J, Lehmann C, Luger P. *J. Am. Chem. Soc.* 1991;113:910-923.
- [21] Paterson I, Norcross RD, Ward RA, Romea P, Lister MA. *J. Am. Chem. Soc.* 1994;116:11287-11314.
- [22] Stork G, Paterson I, Lee FKC. *J. Am. Chem. Soc.* 1982;104:4686.
- [23] Sviridov AF, Ermolenko MS, Yashunsky DV, Borodkin VS, Kochetkov NK. *Tetrahedron Lett.* 1987;28:3835-3838.